Floatz logo

gsk356278

Depressive Disorder and Anxiety Disorders

GlaxoSmithKlineSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Depressive Disorder and Anxiety Disorders cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Massachusetts General Hospital
Phase 4BB
TENOFOVIR DISOPROXIL FUMARATE
Azienda Ospedaliera San Gerardo di Monza
Phase 4BB
(±)-FTC
Azienda Ospedaliera San Gerardo di Monza
Phase 4BB
Azithromycin
University of California, San Francisco
Phase 4BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB

View all 19 →

Same molecule, other indications

gsk356278 is also rated in:

Huntington diseaseDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →